In KRAS-mutant lung cancers and colon cancer, MEK inhibition can activate the MAP2K4-JNK-JUN feedback loop, leading to activation, especially of ERBB3 and FGFR1, which can reactivate MEK and AKT signaling [148,149]. Here, MAP2K7 is linked to malignant colon neoplasm.